Apolloni, S.; Fabbrizio, P.; Amadio, S.; Napoli, G.; Freschi, M.; Sironi, F.; Pevarello, P.; Tarroni, P.; Liberati, C.; Bendotti, C.;
et al. Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model. Int. J. Mol. Sci. 2021, 22, 10649.
https://doi.org/10.3390/ijms221910649
AMA Style
Apolloni S, Fabbrizio P, Amadio S, Napoli G, Freschi M, Sironi F, Pevarello P, Tarroni P, Liberati C, Bendotti C,
et al. Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model. International Journal of Molecular Sciences. 2021; 22(19):10649.
https://doi.org/10.3390/ijms221910649
Chicago/Turabian Style
Apolloni, Savina, Paola Fabbrizio, Susanna Amadio, Giulia Napoli, Mattia Freschi, Francesca Sironi, Paolo Pevarello, Paola Tarroni, Chiara Liberati, Caterina Bendotti,
and et al. 2021. "Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model" International Journal of Molecular Sciences 22, no. 19: 10649.
https://doi.org/10.3390/ijms221910649
APA Style
Apolloni, S., Fabbrizio, P., Amadio, S., Napoli, G., Freschi, M., Sironi, F., Pevarello, P., Tarroni, P., Liberati, C., Bendotti, C., & Volonté, C.
(2021). Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model. International Journal of Molecular Sciences, 22(19), 10649.
https://doi.org/10.3390/ijms221910649